TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* \>18 years old,~* ESLD MELD \<25,~* No recent infection,~* no hepatic decompensation,~* no history of HIV,~* weight \> 110 lbs,~* platelets \> 50,000,~* HGB \>10,~* no prior organ transplant~Exclusion Criteria:~* Patients ineligible for liver transplant,~* patients who do not understand why the study procedures are being conducted,~* subjects who do not meet all inclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Leaukapheresis of End Stage Liver Disease Patients (Type: OTHER): Leukapheresis. All subjects will receive the same treatment arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Stereotaxis Computed Tomography (CT) Co-Registration Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be between 18-80 years of age~* Willing and able to provide prior written informed consent~* Patients present with a single bifurcated lesion or single non-CTO complex lesion requiring PCI.~* Able to be safely exposed to magnetic fields, such as magnetic resonance imaging (MRI)~* CT angiography performed prior to cardiac catheterization (must be performed \>48 hours prior to procedure to limit peri-procedural contrast use, but \<12 months prior to the procedure)~Exclusion Criteria:~* Patients with a creatinine greater than 2.0 mg/dL~* Exclude patients whom in the Investigator's opinion, are hemodynamically unstable on the day of the procedure.~* Untreatable allergy to contrast media~* Patients who have undergone CT angiography within 48 hours of index PCI procedure~* Patients with chronic total occlusions (CTOs) requiring intervention.~* Patients requiring treatment for lesions other than the single bifurcated or single non-CTO complex lesion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group A-CT Coregistration (Type: ACTIVE_COMPARATOR): 5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
- Group B-Angiographic (Type: ACTIVE_COMPARATOR): 5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
- Group C-Standard Angiography (Type: ACTIVE_COMPARATOR): 5 subjects with standard angiography in a conventional PCI (Group C)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with severe burn injuries ≥ 40 % of TBSA (Total Body Surface Area)~* Thermal burn on symmetrical areas allowing grafting of 4 contiguous dermal substrates (cellularised LG002 or uncellularised LG002) on each area~* The patient himself, or his legal representative, must give his informed consent in writing~Exclusion Criteria:~* Anterior progressive serious illness (i.e severe hepatic insufficiency, immunodepression induced by corticotherapy or illness (AIDS))~* Metabolic disease~* Systemic infection or local burn infection~* Known allergy to collagen, streptomycin, Penicillin and/or bovine origine products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cellularised LG002 (Type: EXPERIMENTAL): Cellularised LG002
- UnCellularised LG002 (Type: EXPERIMENTAL): UnCellularised LG002

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Vitamin D on Disease Activity in Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* newly diagnosis with an active Crohn's disease,~* age above of 16 years~Exclusion Criteria:~* remission or the duration of disease is more than 2 years,~* pregnancy,~* liver or kidney failure,~* inability to take oral supplements or medicine

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group 3 (Type: EXPERIMENTAL): Vitamin D3, 10,000 IU daily
- Group 2 (Type: EXPERIMENTAL): Vitamin D3 2,000 IU daily
- Group 1 (Type: EXPERIMENTAL): Vitamin D3 600 IU daily (Control group, RDA level)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neurofeedback In Treatment Resistant Depression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagosis with MDD according to the DSM-IV-TR criteria for MDD, and especially treatment-resistant MDD (Hamilton Rating Scale for Depression \[HAM-D\] score ⩾14) despite adequate antidepressant therapy)~Exclusion Criteria:~* Psychosis~* Bipolar disorder~* Brain injury~* Clinically diagnosed neurological disorder~* Convulsive disorder~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- neurofeedback augmentation group (Type: EXPERIMENTAL): The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. The neurofeedback protocol was determined considering the patient's main symptoms. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.
- medication-only (treatment as usual, TAU) group (Type: ACTIVE_COMPARATOR): To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study.
- healthy controls (Type: NO_INTERVENTION): The healthy controls provided blood samples using the same procedure at baseline only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. American Society of Anesthesiologists (ASA) physical status 1-3~2. Age 18-79, inclusive~3. BMI \<36 kg/m\^2~4. Patient consenting to single injection brachial plexus nerve block as primary anesthetic for a procedure~Exclusion Criteria:~1. Patients with coagulation disorders~2. Clinically significant pulmonary disease~3. Clinically significant cardiac disease~4. Neurologic deficit in surgical extremity~5. Allergy to bupivacaine or buprenorphine~6. Intolerance of narcotics~7. Local infection over intended area of needle insertion~8. Hepatic failure or renal failure~9. Significant psychiatric disease, including drug abuse~10. Seizure disorder~11. Possible pregnancy or lactation by patient report~12. Use of narcotic medication greater than 2 times a week for greater than 1 week.~13. Patients for whom the surgeon requests a shorter-acting block

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): will get only local anesthetic and epinephrine in block. no additive in block
- buprenorphine (Type: EXPERIMENTAL): will receive local anesthetic, epinephrine and the additive buprenorphine to nerve block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Everolimus on CKD Progression in ADPKD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects over 18 years of both genders~2. Clinical diagnosis of autosomal dominant polycystic kidney disease (ADPKD)~3. GFR, according to MDRD formula, between 30 and 90 ml/min/1.73 mq~4. Previous follow up of two years, with a creatinine evaluation at least once a year~5. GFR reduction of at least 2.5 ml/min/year (according to MDRD formula)~Exclusion Criteria:~1. Pregnancy, lactating, males and females without adequate contraception~2. Leucopenia (\< 3,000 leucocytes/mm3) or thrombocytopenia (\< 100,000 platelets/mm3)~3. Dyslipidemia (cholesterol or triglycerides \> 260 mg/dl with treatment)~4. Urinary tract infection~5. Patients who cannot undergoing NMR

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus (Type: EXPERIMENTAL): Everolimus + standard therapy for CKD
- Control (Type: NO_INTERVENTION): Standard therapy for CKD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Mitral Regurgitation on Coronary Haemodynamics and Instantaneous Effect of Transcatheter Mitral Valve Repair

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years;~2. Patients with significant degenerative or functional MR planned for TMVR with the percutaneous edge-to-edge mitral valve repair MitraClip system;~3. Patients with ≥ 1 coronary artery lesion with angiographically-documented ≥50% diameter stenosis,~4. Patient willing and able to provide written informed consent.~Exclusion Criteria:~1. Previous coronary artery bypass surgery;~2. Presence of ≥1 coronary total occlusion(s);~3. Documented non-viable myocardium in the area of the corresponding coronary artery being studied;~4. Severe left ventricular systolic dysfunction (\<30%);~5. Cardiogenic shock/hemodynamic instability at the time of intervention (heart rate\<50 beats per minute, systolic blood pressure \<90mmHg) and/or need for mechanical/pharmacologic hemodynamic support;~6. Systolic pulmonary artery pressure \> 70 mmHg on baseline echocardiography;~7. Significant contraindication to adenosine administration (e.g. heart block, severe asthma);~8. Extremely calcified or tortuous vessels precluding invasive coronary physiology measurement;~9. Acute coronary syndrome with recent ST-elevation myocardial infarction \<5 days prior to randomization, or ongoing non-ST elevation acute coronary syndrome with biomarkers (cardiac troponin) still rising;~10. Hypertrophic cardiomyopathy, restrictive pericarditis, constrictive pericarditis, infiltrative cardiomyopathy;~11. Participation or planned participation in another clinical trial, except for observational registries;~12. Patients unable or unwilling to provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transcatheter Mitral Valve Repair arm (Type: EXPERIMENTAL): Patients with severe Mitral Insufficiency with concomitant intermediate coronary artery stenosis undergoing Transcatheter Mitral Valve Repair using the percutaneous edge-to-edge MitraClip system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Palliative Radiotherapy With or Without Carboplatin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with locally advanced or metastatic bronchial or head and neck cancer~* Patient require palliative radiotherapy~* Age ≥ 18 years~* PS ≤ 2~* Obtaining the signed written consent of the patient~* Patient affiliated to a social security scheme~Exclusion Criteria:~* Other chemotherapy or targeted therapy~* Prior radiation~* Patients with thrombopenia \< 100 000~* Patients with neutropenia \< 2000~* Patients with renal clearance \< 20 mL/min~* Known hypersensitivity to platinum salt~* Treatment with phenytoin or fosphenytoin~* In previous three months, a vaccination against yellow fever, live vaccin or live attenuated vaccine~* Unchecked diabetes~* hemorrhagic tumor~* Refusal of participation or inability to issue informed consent~* Person deprived of liberty or adult under guardianship~* Minor patients, pregnant or lactating women~* Participation in other interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- irradiation + carboplatin (Type: EXPERIMENTAL): Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Carboplatin. :10 injections 1h prior irradiation
- irradiation + placebo (Type: PLACEBO_COMPARATOR): Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Placebo :10 injections 1h prior irradiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* To be eligible to receive continued treatment, subjects must remain eligible to receive study drug at the time of their last Biomed 777-CLP-29 visit~* To continue on survival follow-up, subjects must be in survival follow-up in study Biomed 777-CLP-29~* Written informed consent obtained for subjects who continue study drug treatment~Exclusion Criteria:~* Subjects who have withdrawn consent to participate in Biomed 777-CLP-29 for any reason~* Subjects for whom the investigator considers study participation is no longer in the best interest of those subjects.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age 18 to 64 years~* Women must either be unable to become pregnant (are surgically sterile or postmenopausal) or must use an approved method of birth control throughout the study period.~* Self- reported CPP defined as pelvic pain that is non-cyclical and of at least 6 months duration and refractory to other treatments~* Subject agrees to not start any new treatment (medication or otherwise) throughout the study treatment and follow up periods.~* Subject agrees to maintain stable doses of all current medications throughout the study treatment and follow-up period.~Exclusion Criteria:~* Pacemaker~* History of seizures during the last 2 years or diagnosis of epilepsy~* Currently using tobacco~* Parkinson's Disease~* Any condition, including neurological or psychiatric illness, which per investigators' judgement may increase subject risk~* History of Hunner's lesion in the medical record~* Lactation, pregnancy, or refusal to use medically approved/reliable birth control in women of child-bearing potential~* Sacral, pudendal Interstim® or spinal cord stimulator that is on.~* Contraindications to tDCS stimulation (e.g. metal in the head, implanted brain medical devices, scalp wounds or infections, etc.)~* History of head injury resulting in more than a momentary loss of consciousness during the last 2 years~Note: For the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Guided imagery plus active tDCS (Type: EXPERIMENTAL): Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
- Guided imagery plus Sham tDCS (Type: SHAM_COMPARATOR): Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will be turned off. The device will remain in place, however, for 20 minutes while the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe in Patients Hypo-responsive to Statins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will need to have an LDL-C level of 130 mg/dl or greater without treatment.~* They must have demonstrated an initial LDL-C reduction of less than 25% on 10 mg of atorvastatin or 20 mg of simvastatin.~* Eligible patients will be those deemed by their physicians to be eligible for lipid lowering therapy with a statin and to have stable CAD, CAD equivalent per NCEP guidelines, or Framingham risk of 10-20%.~Exclusion Criteria:~* Recent (\<3 months) diagnosis of Acute Coronary Syndromes due to ethical considerations \[10\].~* Pregnant patients, those planning to become pregnant, or those who are breast feeding, those with liver disease, history allergic reaction to any agent used in the trial, history of myositis, myopathy, pancreatitis, hypertriglyceridemia (TG \> 400 mg/dL), history of significant alcohol or drug abuse, history of organ transplantation, or patient refusal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: PLACEBO_COMPARATOR): None
- Atorvastatin/Ezetimibe (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With hOKT3gamma1(Ala-Ala) in T1DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with T1DM within the past 6 weeks~* have a body weight ≥26 kg at the time of enrollment~* have detectable anti-GAD, anti-ICA512/IA-2, or insulin autoantibodies (if the participant has been on insulin ≤10 days).~Exclusion Criteria:~* Pregnant or lactating females;~* Prior OKT3 treatment;~* Known hypersensitivity to murine products;~* Uncompensated heart failure or fluid overload, recent myocardial infarction;~* History of epilepsy, cancer, active infection, atopic disease, active Grave's disease, cystic fibrosis, sickle cell anemia, neuropathy, peripheral vascular disease, cerebrovascular disease, any concurrent autoimmune diseases, asthma;~* Any medical condition that in the opinion of the investigator will interfere with safe completion of the trial;~* Inability to give informed consent;~* Prior participation in a clinical trial that could potentially affect diabetes or immunologic status;~* Participation in a clinical trial within the last 6 weeks;~* HIV positive;~* Positive for Hepatitis B surface antigen or Anti-Hepatitis C antibody;~* Seropositivity for Toxoplasmosis (IgG);~* Lymphopenia (\<1000 lymphocytes/microliter);~* Thrombocytopenia (\<150,000/mm3 platelets);~* Anemia (Hgb \< 10g/dL);~* Vaccination with a live virus within the past 6 weeks;~* Positive PPD skin test;~* Any infectious mononucleosis-like illness within the 3 months prior to enrollment;~* Serologic evidence of acute infection with EBV or CMV based on tests listed and as defined by the protocol.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): None
- Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues